



ASX Announcement

19 November 2024

Results of 2024 Annual General Meeting

SYDNEY Australia, 19 November 2024 – Atomo Diagnostics Limited (ASX: **AT1**) (**Atomo** or the **Company**) refers to the 2024 Annual General Meeting Results announcement on 15 November 2024 and advises that in accordance with ASX Listing Rule 3.13(2)(f), more than 25% of the votes cast on Resolution 1 were against the adoption of the 2024 remuneration report, which constitutes a 'second strike' for the purposes of the Corporations Act 2001 (Cth).

While the Company received a second strike on its remuneration report, given Resolution 5 was not passed, the Company is not required to hold a spill meeting in relation to the composition of the Board.

This announcement was authorised by the Managing Director & CEO on behalf of the Board.

~ ENDS ~

For more information, please contact:

John Kelly

Managing Director & CEO

e. john.kelly@atomodiagnostics.com

p. +61 401 922 279

Investor Queries

investorqueries@atomodiagnostics.com

About Atomo

Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health. See more at www.atomodiagnostics.com